Integration and Evaluation of Clinical Decision Support Systems for Diagnosis Idopathics Pulmonary Fibrosis (IPF)

Integration and Evaluation of Clinical Decision Support Systems for Diagnosis Idopathics Pulmonary Fibrosis (IPF)

ObjectivesThe purpose of this study was to develop clinical decision support systems (CDSS) that are integrated with hospital information systems for the differential diagnosis of idiopathic pulmonary fibrosis (IPF).MethodsThe integrated CDSS were validated and evaluated by physicians. Knowledge mod...

Full description

Bibliographic Details
Main Authors:	Yunhee Lee, Youngmoon Chae, Sungwan Jeon
Format:	Article
Language:	English
Published:	The Korean Society of Medical Informatics 2010-12-01
Series:	Healthcare Informatics Research
Subjects:	clinical decision support systems idiopathic pulmonary fibrosis computer vision system radiology information systems
Online Access:	http://e-hir.org/upload/pdf/hir-16-260.pdf

Similar Items

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
by: James Patrick Finnerty, et al.
Published: (2021-12-01)

Factors associated with listing for lung transplantation in IPF patients: An analysis of the pulmonary fibrosis foundation registry
by: Christopher S. King, et al.
Published: (2023-08-01)

Idiopathic pulmonary fibrosis: current diagnosis and treatment
by: Alexandre Franco Amaral, et al.
Published: (2023-08-01)

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis
by: Andreas Guenther, et al.
Published: (2018-07-01)

Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis
by: Tejaswini Kulkarni, et al.
Published: (2024-03-01)

Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry
by: Yangjin Jegal, et al.
Published: (2022-04-01)

Imaging in idiopathic pulmonary fibrosis: diagnosis and mimics
by: Bruno Hochhegger, et al.
Published: (2019-02-01)

Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)
by: Ekaterina Krauss, et al.
Published: (2019-07-01)

Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg)
by: Ekaterina Krauss, et al.
Published: (2020-11-01)

Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry
by: Helen E. Jo, et al.
Published: (2018-01-01)

Evaluation of Regional Pulmonary Ventilation in Spontaneously Breathing Patients with Idiopathic Pulmonary Fibrosis (IPF) Employing Electrical Impedance Tomography (EIT): A Pilot Study from the European IPF Registry (eurIPFreg)
by: Ekaterina Krauss, et al.
Published: (2021-01-01)

Multiple complications of advanced IPF in an individual patient presentation
by: Thomas Ledger, et al.
Published: (2023-04-01)

Untargeted Metabolomics Reveals Alterations of Rhythmic Pulmonary Metabolism in IPF
by: Wei Sun, et al.
Published: (2023-10-01)

Sex Differences in the Incidence and Outcomes of Patients Hospitalized by Idiopathic Pulmonary Fibrosis (IPF) in Spain from 2016 to 2019
by: Belén López-Muñiz Ballesteros, et al.
Published: (2021-08-01)

Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry
by: Michael Kreuter, et al.
Published: (2017-07-01)

Towards a better diagnosis of idiopathic pulmonary fibrosis
by: D. Valeyre
Published: (2011-06-01)

Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry
by: Jing Gao, et al.
Published: (2021-02-01)

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
by: Colin H. Holtze, et al.
Published: (2020-02-01)

The Potential Effects of Curcumin on Pulmonary Fibroblasts of Idiopathic Pulmonary Fibrosis (IPF)—Approaching with Next-Generation Sequencing and Bioinformatics
by: Wei-An Chang, et al.
Published: (2020-11-01)

Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America
by: Iván Cherrez-Ojeda, et al.
Published: (2018-01-01)

Angiotensin II type 1 and 2 receptors and lymphatic vessels modulate lung remodeling and fibrosis in systemic sclerosis and idiopathic pulmonary fibrosis
by: Edwin Roger Parra, et al.
Published: (2014-01-01)

Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls
by: Kristina Krempaska, et al.
Published: (2020-01-01)

Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018-01-01)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018-12-01)

Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in a Prospective Registry of Interstitial Lung Diseases in Eastern Siberia
by: Maria S. Nashatyreva, et al.
Published: (2023-01-01)

Molecular genetics of idiopathic pulmonary fibrosis
by: R. N. Mustafin
Published: (2022-06-01)

IPF patients are limited by mechanical and not pulmonary-vascular factors – results of a derivation-validation cohort study
by: Benjamin D. Fox, et al.
Published: (2019-12-01)

HSP90 Inhibition and Modulation of the Proteome: Therapeutical Implications for Idiopathic Pulmonary Fibrosis (IPF)
by: Ruben Manuel Luciano Colunga Biancatelli, et al.
Published: (2020-07-01)

Idiopathic pulmonary fibrosis - a disorder of alveolar wound repair?
by: Swiss Medical Weekly
Published: (2003-07-01)

Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry
by: Helen E. Jo, et al.
Published: (2019-05-01)

The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry
by: Michael Kreuter, et al.
Published: (2019-03-01)

The impact of emphysema in pulmonary fibrosis
by: Vincent Cottin
Published: (2013-06-01)

Idiopathic Pulmonary Fibrosis and Telomeres
by: Alba Mulet, et al.
Published: (2022-11-01)

Senescent Cells in IPF: Locked in Repair?
by: Silke Meiners, et al.
Published: (2020-12-01)

Incidence and Clinical Characteristics of Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis
by: Wei Yan, et al.
Published: (2015-01-01)

Exosomal circRNAs in the plasma serve as novel biomarkers for IPF diagnosis and progression prediction
by: Wenhua Gan, et al.
Published: (2024-03-01)

Clinicopathological Outlines of Post-COVID-19 Pulmonary Fibrosis Compared with Idiopathic Pulmonary Fibrosis
by: Roxana-Elena Cîrjaliu, et al.
Published: (2023-06-01)

Comorbidities and Complications in Idiopathic Pulmonary Fibrosis
by: Esteban Cano-Jiménez, et al.
Published: (2018-08-01)

Machine Learning and Single-Cell Analysis Identify Molecular Features of IPF-Associated Fibroblast Subtypes and Their Implications on IPF Prognosis
by: Jiwei Hou, et al.
Published: (2023-12-01)

Immune Mechanisms of Pulmonary Fibrosis with Bleomycin
by: Yuko Ishida, et al.
Published: (2023-02-01)